En vivo
FierceBiotechWhen Spray Drying Falls Short: A Faster Path ForwardFierceBiotechNovo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 winFierceBiotechRoche boosts diagnostics offerings with $595M Saga buyoutFierceBiotechLilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7BFierceBiotechBiogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibodyModernaWhat's Pushing Moderna Stock Higher Today? - BenzingaNovo NordiskNovo Nordisk to seek oral sickle cell therapy approval after Phase III victory - YahooAbbottDiane Abbott criticises Keir Starmer over Peter Mandelson vetting process - Sky NewsIntuitive SurgicalIntuitive Surgical Q1 2026 Earnings Preview (ISRG:NASDAQ) - Seeking AlphaThermo FisherThermo Fisher: Great Business Still Trading At A Risky Price Before Earnings (NYSE:TMO) - Seeking AlphaThermo FisherHere's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today - BenzingaBioWorldBiggest gainers and losers for April 13-17, 2026
FierceBiotech 27 mar 2026

Novartis pens $2B deal for allergy biotech with potential Xolair successor

Novartis pens $2B deal for allergy biotech with potential Xolair successor

Original
Contenido no disponible. Consulta la fuente original.